Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Krystal BiotechFRA:4KB -1.18%55 EV-to-OCF is 32.67 as of Aug. 10, 2026, which is 21% above its 10-year median of 26.95. GuruFocus rates FRA:4KB with a GF Score™ of 55/100 and a GF Value™ of €291.66 (Fairly Valued). The stock has 2 warning signs investors should review. Among 1,405 Biotechnology companies, Krystal Biotech ranks worse than 92.46% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Krystal Biotech's Enterprise Value is €7,658.8 Mil.
Krystal Biotech's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was €234.4 Mil. Therefore, Krystal Biotech's EV-to-OCF for today is 32.67.
The historical rank and industry rank for Krystal Biotech's EV-to-OCF or its related term are showing as below:
FRA:4KB'
s EV-to-OCF Range Over the Past 10 Years
Min: -345.34 Med: 26.95 Max: 85.06
Current: 32.41
During the past 10 years, the highest EV-to-OCF of Krystal Biotech was 85.06. The lowest was -345.34. And the median was 26.95.
FRA:4KB's EV-to-OCF is ranked worse than 92.46% of 1405
companies
in the Biotechnology industry
Industry Median: -3.45
vs FRA:4KB: 32.41
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Krystal Biotech's PE Ratio (TTM) for today is calculated as:
Krystal Biotech's share price for today is €275.50.
Krystal Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €6.855.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Krystal Biotech EV-to-OCF Related Terms
Krystal Biotech EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Krystal Biotech's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Krystal Biotech's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Krystal Biotech EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Krystal Biotech's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Krystal Biotech's EV-to-OCF falls into.
Krystal Biotech's current Enterprise Value is €7,658.8 Mil.
Krystal Biotech's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €234.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Krystal Biotech (FRA:4KB) has a EV-to-OCF of 32.67 as of Aug. 10, 2026. This is 21% above median its historical median of 26.95. According to the industry distribution chart, Krystal Biotech ranks #1299 out of 1405 companies in the Biotechnology industry, placing it in the top 92.5%.
Is Krystal Biotech's EV-to-OCF too high?
Krystal Biotech's current EV-to-OCF of 32.67 is 21% above median its 10-year median of 26.95. Based on the distribution chart, Krystal Biotech ranks #1299 out of 1405 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Krystal Biotech has a GF Score™ of 55/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Krystal Biotech's EV-to-OCF compare to NUVL and HALO?
According to the Biotechnology industry distribution chart, Krystal Biotech ranks #1299 out of 1405 companies for EV-to-OCF. This places Krystal Biotech in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Krystal Biotech's current EV-to-OCF is 32.67, which is 21% above median its own 10-year median of 26.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Krystal Biotech stock overvalued right now?
Based on GuruFocus' analysis, Krystal Biotech (FRA:4KB) is currently considered Fairly Valued. The stock's GF Value™ is €291.66, compared to a current price of €275.50 — trading 5.5% below its estimated fair value. The current EV-to-OCF is 32.67, which is 21% above median its 10-year median of 26.95. Krystal Biotech's overall GF Score™ is 55/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Krystal Biotech (FRA:4KB), the current EV-to-OCF is 32.67 as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Krystal Biotech (FRA:4KB) Overvalued in 2026?
Based on GuruFocus' analysis, Krystal Biotech stock appears to be undervalued.
The current stock price of €275.50 is trading 5.5% below its estimated GF Value™ of €291.66.
GuruFocus considers Krystal Biotech to be Fairly Valued.
Key valuation signals for FRA:4KB:
EV-to-OCF: 32.67 (21% above median its 10-year median of 26.95)
GF Value™: €291.66 vs. price of €275.50 (5.5% below fair value)
No single metric tells the full story. See the FRA:4KB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.
55GF Score
Get the complete analysis for FRA:4KB
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4KB has been successfully added to your 
